Xtant Medical Holdings, Inc., formerly Bacterin International Holdings, Inc., develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. The Company operates through the development, manufacture and marketing of regenerative medical products and devices segment. Its biomaterial products include OsteoSponge, OsteoSponge SC, OsteoSelect DBM putty, OsteoSelect Plus DBM putty, OsteoWrap, BacFast HD, OsteoSTX, hMatrix and 3Demin products, as well as other allografts. Its products serve the needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, foot and ankle surgeries. It also processes and distributes sports allografts, milled spinal allografts and allografts for multi-disciplinary applications.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryN/A
SectorN/A
Phone+1-406-3880480
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
OptionableNot Optionable
Xtant Medical (NYSEAMERICAN:XTNT) Frequently Asked Questions
What is Xtant Medical's stock symbol?
Xtant Medical trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "XTNT."
When did Xtant Medical's stock split? How did Xtant Medical's stock split work?
Shares of Xtant Medical reverse split on Wednesday, February 14th 2018. The 1-12 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of Xtant Medical stock prior to the reverse split would have 8 shares after the split.
How were Xtant Medical's earnings last quarter?
Xtant Medical Holdings Inc (NYSEAMERICAN:XTNT) announced its quarterly earnings results on Wednesday, November, 14th. The medical device company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.27) by $0.03. The medical device company earned $17.27 million during the quarter. View Xtant Medical's Earnings History.
When is Xtant Medical's next earnings date?
What price target have analysts set for XTNT?
1 brokerages have issued 1-year target prices for Xtant Medical's stock. Their predictions range from $6.00 to $6.00. On average, they expect Xtant Medical's stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 167.9% from the stock's current price. View Analyst Price Targets for Xtant Medical.
What is the consensus analysts' recommendation for Xtant Medical?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xtant Medical in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Xtant Medical.
Has Xtant Medical been receiving favorable news coverage?
News headlines about XTNT stock have trended somewhat positive on Saturday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Xtant Medical earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the medical device company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are Xtant Medical's key executives?
Xtant Medical's management team includes the folowing people:
- Carl D. O'Connell, President, Chief Executive Officer (Age 53)
- Darrel Lee Holmes, Chief Operating Officer (Age 62)
- Gregory Juda Ph.D., Chief Scientific Officer (Age 39)
- John K. Bakewell, Director (Age 55)
- Michael Eggenberg, Director
- Michael R. Mainelli Jr., Director (Age 55)
- Robert E. McNamara, Director (Age 61)
- Jeffrey J. Peters, Director
How do I buy shares of Xtant Medical?
Shares of XTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Xtant Medical's stock price today?
One share of XTNT stock can currently be purchased for approximately $2.24.
What is Xtant Medical's official website?
How can I contact Xtant Medical?
Xtant Medical's mailing address is 664 Cruiser Ln, BELGRADE, MT 59714-9719, United States. The medical device company can be reached via phone at +1-406-3880480.
MarketBeat Community Rating for Xtant Medical (NYSEAMERICAN XTNT)
MarketBeat's community ratings are surveys of what our community members think about Xtant Medical and other stocks. Vote "Outperform" if you believe XTNT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe XTNT will underperform the S&P 500 over the long term. You may vote once every thirty days.
